Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
NCT01275664 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4
Last updated 2018-05-22
Summary
This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
Conditions
- Nausea and Vomiting
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Cystadenocarcinoma
- Stage II Ovarian Cancer
- Stage IIA Fallopian Tube Cancer
- Stage IIA Ovarian Cancer
- Stage IIB Fallopian Tube Cancer
- Stage IIB Ovarian Cancer
- Stage IIC Fallopian Tube Cancer
- Stage IIC Ovarian Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Primary Peritoneal Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Primary Peritoneal Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Primary Peritoneal Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Cancer
- Stage IV Primary Peritoneal Cancer
- Undifferentiated Ovarian Carcinoma
Interventions
- PROCEDURE
-
Adjuvant Therapy
Ancillary studies
- DRUG
-
Aprepitant
Given IV and PO
- DRUG
-
Given IP
- DRUG
-
Given IP
- DRUG
-
Given PO
- DRUG
-
Granisetron Transdermal Patch
Apply one patch to upper arm
- PROCEDURE
-
Management of Therapy Complications
Ancillary studies
- OTHER
-
Questionnaire Administration
Ancillary studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Gynecologic Oncology Group
lead NETWORK
Principal Investigators
-
Steven Plaxe · NRG Oncology
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-06-30
- Primary Completion
- 2014-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
NCT00104403 ·Status: COMPLETED ·Phase: PHASE2
-
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
NCT00343863 ·Status: COMPLETED ·Phase: NA
-
Low Dose Aprepitant for Patients Receiving Carboplatin
NCT03237611 ·Status: TERMINATED ·Phase: PHASE2
-
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
NCT04503668 ·Status: TERMINATED ·Phase: PHASE3
-
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01432015 ·Status: COMPLETED ·Phase: PHASE4
-
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
NCT00687011 ·Status: COMPLETED ·Phase: PHASE4
-
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00553059 ·Status: COMPLETED ·Phase: PHASE3
-
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
NCT01649258 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
NCT00891761 ·Status: WITHDRAWN ·Phase: PHASE3
-
Anti-emetic Prophylaxis With or Without Dexamethasone
NCT05242874 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
NCT00475085 ·Status: COMPLETED ·Phase: PHASE3
-
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
NCT04912271 ·Status: UNKNOWN ·Phase: PHASE3
-
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
NCT02116530 ·Status: COMPLETED ·Phase: PHASE3
-
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
NCT00337727 ·Status: COMPLETED ·Phase: PHASE3
-
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
NCT00869973 ·Status: TERMINATED ·Phase: PHASE3
-
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT00366834 ·Status: COMPLETED ·Phase: PHASE3
-
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
NCT00895245 ·Status: TERMINATED ·Phase: PHASE2
-
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
NCT02484911 ·Status: COMPLETED ·Phase: PHASE3
-
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT01736917 ·Status: COMPLETED ·Phase: PHASE2
-
Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease
NCT00005024 ·Status: UNKNOWN ·Phase: PHASE3
-
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
NCT04201769 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
NCT03668639 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
NCT00869310 ·Status: TERMINATED ·Phase: PHASE3
-
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
NCT02106494 ·Status: COMPLETED ·Phase: PHASE3
-
Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone
NCT02532634 ·Status: COMPLETED ·Phase: PHASE4